兄弟科技(002562.SZ):子公司收到碘海醇原料藥上市申請批准通知書
格隆匯4月8日丨兄弟科技(002562.SZ)公佈,公司全資子公司江西兄弟醫藥有限公司(以下簡稱“兄弟醫藥”)於近日收到國家藥品監督管理局核准簽發的《化學原料藥上市申請批准通知書》。
藥品的基本情況
1、化學原料藥名稱:碘海醇
2、包裝規格:25kg/桶
3、通知書編號:2024YS00262
4、生產企業:江西兄弟醫藥有限公司
5、申請事項:境內生產化學原料藥上市申請
6、審批結論:根據《中華人民共和國藥品管理法》及有關規定,經審查,本品符合藥品註冊的有關要求,批准本品註冊生產。生產工藝、質量標準和標籤照所附執行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.